Lastly, the study was limited to women with a BMI between 24 and 40 kg/m2 and Her2/neu-negative breast cancer who received chemotherapy, potentially restricting the generalizability of our findings to a broader population. This evidence concerns the gene ERBB2 and breast cancer.